Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey

NCT06545877 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT06545877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
September 16, 2022
Completion date
February 28, 2026
Enrollment
571 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infertility